SEC FORM 4SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
checkbox uncheckedCheck this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
checkbox checkedCheck this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McCourt Marion

(Last)(First)(Middle)
777 OLD SAW MILL RIVER ROAD

(Street)
TARRYTOWNNY10591

(City)(State)(Zip)
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]
Foreign Trading Symbol
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
checkbox checkedOfficer (give title below)Other (specify below)
EVP Commercial
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
checkbox checkedForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026S(1)44D$952.79(2)10,827D
Common Stock11/16/2026S(1)59D$954.46(3)10,768D
Common Stock11/16/2026S(1)30D$955.5110,738D
Common Stock11/16/2026S(1)22D$956.0110,716D
Common Stock11/16/2026S(1)44D$958.47(4)10,672D
Common Stock11/16/2026S(1)66D$959.46(5)10,606D
Common Stock11/16/2026S(1)49D$960.31(6)10,557D
Common Stock11/16/2026S(1)59D$961.36(7)10,498D
Common Stock11/16/2026S(1)41D$962.44(8)10,457D
Common Stock11/16/2026S(1)42D$963.7(9)10,415D
Common Stock11/16/2026S(1)21D$964.6910,394D
Common Stock11/16/2026S(1)63D$965.62(10)10,331D
Common Stock11/16/2026S(1)26D$971.9310,305D
Common Stock219IBy 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.
2. Represents volume-weighted average price of sales of 44 shares of Company stock on November 16, 2026 at prices ranging from $952.64 to $952.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
3. Represents volume-weighted average price of sales of 59 shares of Company stock on November 16, 2026 at prices ranging from $954.44 to $954.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
4. Represents volume-weighted average price of sales of 44 shares of Company stock on November 16, 2026 at prices ranging from $958.29 to $958.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
5. Represents volume-weighted average price of sales of 66 shares of Company stock on November 16, 2026 at prices ranging from $959.18 to $959.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
6. Represents volume-weighted average price of sales of 49 shares of Company stock on November 16, 2026 at prices ranging from $960.07 to $960.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
7. Represents volume-weighted average price of sales of 59 shares of Company stock on November 16, 2026 at prices ranging from $961.26 to $961.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
8. Represents volume-weighted average price of sales of 41 shares of Company stock on November 16, 2026 at prices ranging from $962.15 to $962.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
9. Represents volume-weighted average price of sales of 42 shares of Company stock on November 16, 2026 at prices ranging from $963.32 to $963.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
10. Represents volume-weighted average price of sales of 63 shares of Company stock on November 16, 2026 at prices ranging from $965.38 to $965.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
/s/ Marion McCourt11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.